Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.
Company profile
Ticker
IPSC
Exchange
Website
CEO
Lalo Flores
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Century Therapeutics Canada ULC ...
IRS number
842040295
IPSC stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
14 Mar 24
8-K
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Departure of Directors or Certain Officers
19 Jan 24
8-K
Other Events
11 Dec 23
8-K
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
6 Dec 23
8-K
Departure of Directors or Certain Officers
14 Nov 23
8-K
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Other Events
3 Oct 23
Latest ownership filings
144
Notice of proposed sale of securities
20 Mar 24
4
Brent Pfeiffenberger
18 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
Douglas Carr
11 Mar 24
4
Gregory Russotti
11 Mar 24
4
Adrienne Farid
11 Mar 24
4
Hyam Levitsky
11 Mar 24
4
Adrienne Farid
8 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 57.29 mm | 57.29 mm | 57.29 mm | 57.29 mm | 57.29 mm | 57.29 mm |
Cash burn (monthly) | 3.04 mm | 4.67 mm | 11.88 mm | 11.34 mm | 4.55 mm | 7.09 mm |
Cash used (since last report) | 18.21 mm | 27.93 mm | 71.02 mm | 67.83 mm | 27.21 mm | 42.38 mm |
Cash remaining | 39.08 mm | 29.35 mm | -13.74 mm | -10.54 mm | 30.08 mm | 14.91 mm |
Runway (months of cash) | 12.8 | 6.3 | -1.2 | -0.9 | 6.6 | 2.1 |
Institutional ownership, Q2 2023
77.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 67 |
Opened positions | 6 |
Closed positions | 4 |
Increased positions | 20 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 60.75 bn |
Total shares | 50.37 mm |
Total puts | 100.00 |
Total calls | 1.40 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BAYRY Bayer Aktiengesellschaft | 12.68 mm | $201.04 mm |
Versant Venture Capital VI | 11.45 mm | $0.00 |
FUJIFILM Cellular Dynamics | 6.96 mm | $110.31 mm |
FMR | 5.17 mm | $16.33 bn |
Casdin Capital | 3.21 mm | $10.13 bn |
BLK Blackrock | 1.62 mm | $5.10 bn |
DAFNA Capital Management | 1.31 mm | $4.13 bn |
Baker Bros. Advisors | 1.15 mm | $3.63 bn |
Vanguard | 1.15 mm | $3.63 bn |
Avidity Partners Management | 1.11 mm | $3.51 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Mar 24 | Levitsky Hyam | Common Stock | Grant | Acquire A | No | No | 0 | 24,000 | 0.00 | 24,000 |
7 Mar 24 | Levitsky Hyam | Stock Option Common Stock | Grant | Acquire A | No | No | 5.32 | 146,000 | 776.72 k | 146,000 |
7 Mar 24 | Gregory Russotti | Common Stock | Grant | Acquire A | No | No | 0 | 24,000 | 0.00 | 302,319 |
7 Mar 24 | Gregory Russotti | Stock Option Common Stock | Grant | Acquire A | No | No | 5.32 | 146,000 | 776.72 k | 146,000 |
7 Mar 24 | Adrienne Farid | Common Stock | Grant | Acquire A | No | No | 0 | 24,000 | 0.00 | 138,149 |
7 Mar 24 | Adrienne Farid | Stock Option Common Stock | Grant | Acquire A | No | No | 5.32 | 146,000 | 776.72 k | 146,000 |
7 Mar 24 | Douglas Carr | Common Stock | Grant | Acquire A | No | No | 0 | 14,000 | 0.00 | 317,580 |
7 Mar 24 | Douglas Carr | Stock Option Common Stock | Grant | Acquire A | No | No | 5.32 | 81,000 | 430.92 k | 81,000 |
7 Mar 24 | Brent Pfeiffenberger | Common Stock | Grant | Acquire A | No | No | 0 | 17,425 | 0.00 | 1,470,704 |
7 Mar 24 | Brent Pfeiffenberger | Stock Option Common Stock | Grant | Acquire A | No | No | 5.32 | 104,550 | 556.21 k | 104,550 |
News
Canaccord Genuity Maintains Buy on Century Therapeutics, Raises Price Target to $24
15 Mar 24
HC Wainwright & Co. Reiterates Buy on Century Therapeutics, Maintains $13 Price Target
15 Mar 24
Century Therapeutics: Q4 Earnings Insights
14 Mar 24
Century Therapeutics FY EPS $(2.30) Misses $(2.09) Estimate, Sales $2.23M Miss $3.82M Estimate
14 Mar 24
Century Therapeutics To Present Preclinical Data From Its iPSC-Derived Cell Therapy Platform At The 2024 American Association For Cancer Research Annual Meeting
6 Mar 24
Press releases
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
25 Mar 24
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
14 Mar 24
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
5 Mar 24
IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
23 Jan 24